Press Room - Sanofi US News
WEBSep 20, 2024 · SARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Release: Sarclisa approved in the US as the first anti ... - Sanofi
WEBSep 20, 2024 · Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous administration method for Sarclisa in clinical studies.
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Sanofi wins US approval for multiple myeloma drug in newly …
WEBSep 20, 2024 · The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed ...
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple …
WEB4 days ago · This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Press Release: ASCO: Sarclisa is first anti-CD38 to ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB4 days ago · On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult ...
Press Release: Sarclisa induction treatment demonstrated ... - Sanofi
WEBAug 8, 2005 · New results from the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 phase 3 study show that Sarclisa (isatuximab) in combination with lenalidomide, bortezomib, and dexamethasone (RVd) during induction therapy in transplant-eligible, newly diagnosed multiple myeloma (NDMM) significantly prolonged progression ...
Sanofi moves on J&J in first-line myeloma with FDA nod
WEBSep 20, 2024 · Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa. Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with ...
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
WEB4 days ago · Sanofi's Sarclisa gets a shot at taking on Johnson & Johnson, Genmab's Darzalex in first-line multiple myeloma treatment.
- Some results have been removed
Skip to content